Innate immune reprogramming to overcome therapy resistance in high-risk colorectal cancer
Dauer: 36 Monate, Fördersumme: € 800.000
Decoding cellular senescence in glioblastoma (GlioAge)
Dauer: 36 Monate, Fördersumme: € 898.970
Systems medicine analysis of sarcoidosis by targeting mTOR in a co-clinical trial in patients and mice
Dauer: 48 Monate, Fördersumme: € 799.570
Characterizing and targeting the Ewing sarcoma microenvironment to overcome resistance to therapy
Dauer: 48 Monate, Fördersumme: € 799.510